Cortecs adopts radical measures following increasing losses and plummeting share prices
This article was originally published in Clinica
Troubled UK biotechnology company Cortecs has announced a range of measures, including a strategy change, fundraising, a new name and a new chairman, aimed at revitalising its business. Over the past few years, the company has faced increasing losses and disappointing drug development results and seen its share price plummet from around 400p to just 16p. The company's share value fell 1p on the news. The announcement had little impact on the company's share price.
You may also be interested in...
Sandoz has launched an awareness campaign under the banner of “Ask For Generics” in the US. The initiative is aiming to educate stakeholders on the benefits of generics and their quality, safety and efficacy.
European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by Europe’s brand industry. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.
Belgian developer of cancer diagnostics is building an infectious disease portfolio on the back of its new SARS-CoV-2 test and collaborations with Immunexpress and Endpoint Health.